Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06805617 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
A Phase 2 study of Adenoid Cystic Carcinoma and Salivary Gland Cancer, sponsored by Glenn J. Hanna.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 2
- Study locations
NCT06805617 is a Phase 2 study of Adenoid Cystic Carcinoma and Salivary Gland Cancer that is actively recruiting participants, run by Glenn J. Hanna. The registered enrollment target is 35 participants, below the 126-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06805617, a Phase 2 study of Adenoid Cystic Carcinoma and Salivary Gland Cancer, is actively recruiting participants, sponsored by Glenn J. Hanna.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers. The name of the study drug involved in this study is: -Ivonescimab (a type of antibody)
Conditions Studied
Interventions
- DRUG Ivonescimab
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-02-26 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06805617
The ClinicalTrials.gov registry entry for NCT06805617 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (72% lower). The listed sponsor is Glenn J. Hanna, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Adenoid Cystic Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Ivonescimab is the first listed.
NCT06805617 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06805617 about?
NCT06805617 is a clinical study titled "A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers". The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers. The name of the study drug involved in this study is: -Ivonescimab (a type of antibody)
What is the current status of trial NCT06805617?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2025-02-26. Estimated completion is 2027-07-01.
What conditions does trial NCT06805617 study?
This clinical trial studies the following conditions: Adenoid Cystic Carcinoma, Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer.
What interventions are being tested in trial NCT06805617?
The interventions under investigation include: Ivonescimab (DRUG).
Who is sponsoring clinical trial NCT06805617?
This trial is sponsored by Glenn J. Hanna, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06805617 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenoid Cystic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
RECRUITING · Phase 2
-
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
ACTIVE NOT RECRUITING · Phase 2
-
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.